Background {#Sec1}
==========

Several polymorphisms of the apolipoprotein C3 gene (*apoC3*) have been reported, the *Sst*I polymorphism being the most well-known \[[@CR1]--[@CR3]\]. This polymorphism is defined as a C to G conversion in the 3′ untranslated region of exon 4 in the *apoC3* \[[@CR4]\], and has been confirmed to exist in several ethnic groups, including African American, Caucasian, Taiwanese and Chinese populations. There are two alleles of the *Sst*I polymorphism: S1 and S2. Several studies have shown that the rare S2 allele is associated with increased plasma triglyceride (TG) levels, although this association is not always concordant among different ethnic groups \[[@CR5]--[@CR7]\].

The Li population is the smallest minority ethnic group in China, who reside predominantly in Hainan Province, which is not part of Mainland China. However, the existence of the *Sst*I polymorphism in the *apoC3* and the relationship between the S2 allele and plasma TG remain to be confirmed in the Li ethnic group.

Plasma TG is an atherogenic factor that plays a crucial role in the development of atherosclerosis \[[@CR8]--[@CR10]\]. Previous studies have shown that plasma apoCIII is also an independent risk factor for atherosclerosis, and the suppression of apoCIII is associated with decreased risks of atherosclerosis and coronary heart disease (CHD) \[[@CR11]--[@CR14]\]. Plasma apoCIII is also associated with plasma TG \[[@CR3], [@CR4], [@CR6], [@CR7]\]; however, the effects of the S2 allele on the risk of atherosclerosis and the relationships between the S2 allele and plasma levels of TG or apoCIII remain to be clarified in the Li ethnic group.

In this study, we investigated the existence of the *Sst*I polymorphism in the *apoC3* in the Li ethnic group. We also investigated the relationships between the S2 allele and plasma TG or apoCIII levels and their roles in the development of atherosclerosis.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study was approved by the Ethics Committee of the First Affiliated Hospital of Hainan Medical University (Hainan Province, China). Written informed consent was obtained from all subjects and the investigations were carried out in accordance with the principles of the Declaration of Helsinki. From September 2012 to September 2014, a total of 628 subjects were selected randomly from the Li and Han populations to attend our study. This group included 316 atherosclerotic subjects (AS), consisting of 155 Li individuals and 161 Han individuals with an average age of (63.68 ± 12.19 y). In addition, 312 healthy subjects (control) were selected consisting of 158 Li individuals and 154 Han individuals with an average age of (61.75 ± 13.07 y). The age range of the participants was between 41 and 88 y. There was no consanguinity among the participants, whose grandparents and parents were from the same population and resided in Hainan Province. Atherosclerotic subjects were determined by angiographic or ultrasonic detection of atherosclerotic plaques in the carotid or coronary arteries. Patients with a history of inflammatory disease, autoimmune disease, malignant tumors, familial hyperlipidemia or diabetes were excluded. Healthy subjects were screened on the basis of having no history of hypertension, cardiovascular or cerebral disease, and endocrine disease.

Epidemiological survey {#Sec4}
----------------------

An international standard method was applied to survey demographics, socioeconomic status, and lifestyle using a standardized questionnaire to gather and record all information. Smoking status and alcohol status were categorized into two groups: non-smoker and smoker, and non-drinker and drinker. The physical examination included measurements of body height, body weight, waist circumference, blood pressure, electrocardiograms, and body mass index (BMI). Blood pressure referred to the average sitting blood pressure after three measurements made using a mercurial sphygmomanometer. Systolic and diastolic blood pressures referred to the first and the fifth Korotkoff sounds, respectively. BMI was calculated by dividing weight (kg) by squared height (m^2^). Abdominal obesity was defined as waist circumference ≥ 90 cm for males and ≥85 cm for females. Overweight was defined as BMI ≥25 kg/m^2^, and hypertension was diagnosed according to diagnostic criteria based on Chinese Guidelines for Prevention and Treatment of Dyslipidemia in Adults and the 2010 Chinese Guidelines for Prevention and Treatment of Hypertension.

Biochemical analysis {#Sec5}
--------------------

Venous fasting blood samples (10 ml) were obtained after a 12 h overnight fast. From this sample, 6 ml was used for analysis of the serum levels of TG, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), lipoprotein AI (apoAI), lipoprotein B (apoB), apoCIII, lipoprotein a \[Lp(a)\] and fasting blood sugar (FBS). The remaining 4 ml was placed into a tube coated with the anticoagulant ethylene diamine tetra-acetic acid (EDTA) for extraction of deoxyribonucleic acid (DNA). TG, TC, HDL-C, LDL-C, and FBS levels were determined using enzymatic methods; and apoAI, apoB and Lp(a) were assessed using immunoturbidimetric assays with commercially available kits according to the manufacturer's instructions (Pointe Biotech, China). ApoCIII was measured by enzyme-linked immunosorbent assay (Abcam, Cambridge, England). All samples were processed using an autoanalyzer (Type 7600; Hitachi Ltd., Tokyo, Japan) or ELISA plate reader (Biotech, USA) at the First Affiliated Hospital of Hainan Medical University.

DNA amplification and genotyping {#Sec6}
--------------------------------

DNA was extracted from leukocytes present in the anti-coagulant-treated blood sample using a DNA extracting kit (Sigma-Aldrich, USA). Restriction fragment length polymorphism (RFLP) analysis was employed to detect the *Sst*I polymorphism in the *apoC3* gene. The *apoC3* gene was amplified by polymerase chain reaction (PCR) using the following primers: forward 5′-CATGGTTGCCTACAGAGGAGTTC-3′ and reverse 5′-TTTGACCTTCCGCACAAAGCTGT-3′ (Sangon, Shanghai, China) in a total volume containing: 10 μl (300 ng) of template DNA, 2 μl of each primer, 13.5 μl of 2× EcoTaq PCR SuperMix, and 22.5 μl of RNase-Free water. The amplification process was optimized using a T Gradient Thermocycler (Biometra, Germany) with an initial denaturation at 94 °C for 2 min, followed by 35 cycles of denaturation at 95 °C for 1 min, annealing at 56.2 °C for 45 s, and extension at 72 °C for 1 min, with a final extension at 72 °C for 10 min. The amplification products were then subjected to RFLP analysis in a total reaction volume of 25 μl consisting of 10 μl of amplified DNA, 2.5 μl of 10× NEB buffer, 1 μl of *Sst*I restriction enzyme and 11.5 μl of ddH~2~O at 37 °C for 4 h.

DNA sequencing {#Sec7}
--------------

The S1S1, S1S2 and S2S2 genotypes identified by PCR-RFLP were also verified by DNA sequencing of both strands using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Forster City, CA, USA) and an ABI 3730xl DNA Analyzer (Applied Biosystems).

Statistical analysis {#Sec8}
--------------------

Statistical analysis was carried out using SPSS version 20.0 software, and data were presented as mean ± standard deviation (SD). Quantitative values were analyzed by *t*-test. Observed genotypic frequencies were compared to expected genotypic frequencies to assess Hardy--Weinberg equilibrium. The allele frequency of the *Sst*I polymorphism in the *apoC3* was determined by gene counting, and the chi-squared test was employed to test differences between the genotypic and allelic frequencies of the atherosclerotic patients and healthy controls in both the Li and Han ethnic groups. Differences in demographic characteristics were assessed by the chi-squared or *t-*tests. Multiple unconditional logistic regression analysis was employed to evaluate the effects of the *Sst*I polymorphism in the *apoC3* on the risk of atherosclerosis. Differences in the lipid profiles among the different genotypes were evaluated by *t-*test (intergroup comparisons of serum lipid profiles were performed with the Kruskal--Wallis test or the Wilcoxon--Mann--Whitney test). *P*-values \<0.05 were considered to indicate statistical significance.

Results {#Sec9}
=======

Demographic characteristics of atherosclerotic patients and healthy subjects {#Sec10}
----------------------------------------------------------------------------

There were no significant differences between the Li and Han populations included in the study in terms of the male:female ratio, mean age, height and body weight, BMI, smoking status and drinking status (all *P* \> 0.05). Atherosclerotic subjects exhibited greater waist circumference and higher systolic and diastolic blood pressures than healthy subjects (*P* \< 0.01, waist circumference and systolic pressure; *P* \< 0.05, diastolic pressure) (Table [1](#Tab1){ref-type="table"}).Table 1Demographic characteristics of atherosclerotic patients (AS) and healthy controls (control) in the Li and Han ethnic groupsCharacteristicAS (*n* = 316)Control (*n* = 312)*t (χ* ^*2*^ *)P-*valueNationality (Li/Han)155/161158/1540.1590.690Sex (male/female)176/140150/1623.6510.056Age (years)63.68 ± 12.1961.75 ± 13.071.9080.057Height (m)1.65 ± 0.061.64 ± 0.061.7780.076Weight (kg)65.49 ± 7.3564.61 ± 7.321.5110.131BMI (kg/m^2^)24.12 ± 2.2424.06 ± 2.330.3130.755Non-smoker/smoker217/99235/773.4410.064Non-drinker/drinker255/61232/803.6210.057Waist circumference (cm)83.14 ± 3.94\*\*75.34 ± 5.4120.6180.000Systolic pressure (mmHg)139.85 ± 22.05\*\*133.27 ± 11.514.6980.000Diastolic pressure (mmHg)81.93 ± 11.65\*80.28 ± 7.352.1180.035Data represent mean ± SD. BMI: Body mass index, ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01, atherosclerotic patients versus healthy controls analyzed using *χ* ^*2*^-tests or *t*-tests

Determination of the SstI polymorphism in the apoC3 gene {#Sec11}
--------------------------------------------------------

Samples were genotyped on the basis of *Sst*I RFLP analysis of PCR amplification products (Fig. [1](#Fig1){ref-type="fig"}). A single 596 bp fragment indicated homozygosity for the absence of *Sst*I restriction sites; this was defined as the S1S1 genotype (CC). Fragments of 596 bp, 371 bp and 225 bp indicated heterozygosity for the presence and absence of *Sst*I restriction sites; this was defined as the S1S2 genotype (CG). Fragments of 371 bp and 225 bp indicated homozygosity for the presence of *Sst*I restriction sites; this was defined as the S2S2 genotype (GG). Genotypes were confirmed by DNA sequencing (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Genotyping of the *Sst*I polymorphism in the *apoC3* gene by RFLP of PCR amplification products. Lane M, 2000 bp ladder marker; Lane 1, PCR product amplified from blood samples (596 bp); Lanes 2 and 3, S1S1 genotype (596 bp); Lanes 4 and 5, S1S2 genotype (596 bp, 371 bp, 225 bp); Lanes 6 and 7, S2S2 genotype (371 bp, 225 bp) Fig. 2Genotyping of the *Sst*I polymorphism in the *apoC3* gene by DNA sequencing. **a** S1S1 genotype (CC); **b** S1S2 genotype (CG); **c** S2S2 genotype (GG)

Genotypic and allelic frequencies in atherosclerotic patients and healthy controls {#Sec12}
----------------------------------------------------------------------------------

The genotype frequencies of the atherosclerotic patients and healthy controls were in Hardy--Weinberg equilibrium (*P* \> 0.05) (Table [2](#Tab2){ref-type="table"}). However, there were significantly higher frequencies of the S1S2 and S2S2 genotypes among the atherosclerotic patients compared with those among the healthy controls (both *P* \< 0.01). Furthermore, the frequency of the S2 allele was higher in atherosclerotic patients compared with that in the healthy controls (*P* \< 0.01) (Table [3](#Tab3){ref-type="table"}). Further analysis revealed identical patterns in the Li and Han ethnic groups (Table [4](#Tab4){ref-type="table"}).Table 2Hardy--Weinberg equilibrium of the genotype distributions of atherosclerotic patients (AS) and healthy controls (control)GroupFrequency of different genotypes (n, %)*χ* ^*2*^*P*-valueS1S1S1S2S2S2ASActual frequency165 (52.2)129 (40.8)22 (7.0)0.0700.966Theoretical frequency167 (52.8)126 (39.9)23 (7.3)ControlActual frequency239 (76.6)64 (20.5)9 (2.9)0.9970.608Theoretical frequency235 (75.3)71 (22.8)6 (1.9)Data are expressed as numbers and percentages. Actual frequency versus theoretical frequency within atherosclerotic patients and healthy controls analyzed using *χ* ^*2*^ tests Table 3Genotypic and allelic frequencies among atherosclerotic patients (AS) and healthy controls (control)GroupnGenotypic frequencies(n, %)Allelic frequencies (n, %)S1S1S1S2S2S2S1S2AS316165 (52.2)129 (40.8) ^\*\*^22 (7.0) ^\*\*^459 (72.6)173 (27.4) ^\*\*^Control312239 (76.6)64 (20.5)9 (2.9)542 (86.9)82 (13.1)*χ* ^*2*^40.87319.734*P-*value0.0000.000Data are expressed as numbers and percentages. ^\*\*^ *P* \< 0.01, atherosclerotic patients versus healthy controls analyzed using *χ* ^*2*^ tests Table 4Genotypic and allelic frequencies in the Li and Han ethnic groupsEthnic groupGroupnGenotypic frequencies (n, %)Allelic frequencies (n, %)S1S1S1S2S2S2S1S2LiAS15582 (52.9)67 (43.2) ^\*\*^6 (3.9) ^\*\*^231 (74.5)79 (25.5) ^\*\*^Control158122 (77.2)33 (20.9)3 (1.9)277 (87.7)39 (12.3)*χ* ^*2*^20.37617.699*P*-value0.0000.000HanAS16183 (51.6)62 (38.5) ^\*\*^16 (9.9) ^\*\*^228 (70.8)94 (29.2) ^\*\*^Control154117 (76.0)31 (20.1)6 (3.9)265 (86.0)43 (14.0)*χ* ^*2*^20.51321.462*P*-value0.0000.000Data are expressed as numbers and percentages. ^\*\*^ *P* \< 0.01, atherosclerotic patients versus healthy controls in the Li and Han ethnic groups analyzed using *χ* ^*2*^ tests

Multiple unconditional logistic regression analysis of the effects of SStI polymorphism in the apoC3 gene on the risk of atherosclerosis {#Sec13}
----------------------------------------------------------------------------------------------------------------------------------------

In multiple unconditional logistic regression analysis, atherosclerosis was used as the dependent variable (atherosclerosis: yes = 1, no = 0), while the independent variables were as follows: age (≥50 = 1,\<50 = 0), smoking (yes = 1, no = 0), drinking (yes = 1, no = 0), BMI (≥25 = 1,\<25 = 0), *apoC3* genotype (S1S1 = 0, S1S2 or S2S2 = 1). According to the results, the S1S2 and S2S2 *apoC3* genotypes were associated with a 2-fold increase in the risk of atherosclerosis (Table [5](#Tab5){ref-type="table"}), indicating that the S2 allele contributes to susceptibility to atherosclerosis.Table 5The effects of *SSt*I polymorphism in the *apoC3* gene on the risk of atherosclerosisVariableAS (n)Control (n)Adjusted OR95% CIAdjusted *P*-valueLi ethnicity*ApoC3* genotypeS1S1821221S1S2 + S2S273362.461(1.545--3.919)\<0.01Han ethnicity*ApoC3* genotypeS1S1831171S1S2 + S2S278372.899(1.790--4.694)\<0.01The model was adjusted for age, body mass index, smoking status and drinking status. OR: odds ratio, CI: confidence interval. S1S1 genotype versus S1S2 + S2S2 genotype in the Li and Han ethnic groups analyzed using multivariate unconditional logistic regression analysis

Lipid profiles of atherosclerotic and healthy participants in the li and Han ethnic groups {#Sec14}
------------------------------------------------------------------------------------------

FBS, TG, TC, LDL-C, apoB and apoCIII levels were significantly higher in atherosclerotic subjects compared to those in healthy controls, while HDL-C and apoAI levels and the apoAI:apoB ratio were significantly lower (all *P* \< 0.01). There was no significant difference in Lp(a) levels (*P* \> 0.05) between atherosclerotic patients and healthy controls (Table [6](#Tab6){ref-type="table"}). Further analysis revealed differences in the lipid profiles of the Li and Han ethnic groups. Although increased TG, apoB, and apoCIII levels and decreased HDL-C levels were found in both ethnic groups, the apoAI levels and apoAI:apoB ratio were lower among atherosclerotic patients in the Li ethnic group (both *P* \< 0.01) in comparison to those of Han descent, who typically showed increased TC and LDL-C levels and a high apoAI:apoB ratio (all *P* \< 0.01) (Table [7](#Tab7){ref-type="table"}).Table 6Lipid profiles of atherosclerotic patients (AS) and healthy controls (control)ParameterAS (n = 316)Control (n = 312)*tP-*valueFBS (mmol /L)5.88 ± 1.30\*\*5.67 ± 0.482.7950.005TC (mmol /L)5.08 ± 1.10\*\*4.77 ± 0.804.0870.000TG (mmol/L)1.44 ± 1.01\*\*1.15 ± 0.664.2450.000HDL-C (mmol/L)1.12 ± 0.37\*\*1.27 ± 0.32−5.4430.000LDL-C (mmol/L)3.16 ± 0.90\*\*2.83 ± 0.734.9840.000ApoAI (g/L)1.20 ± 0.36\*\*1.28 ± 0.34−2.9640.003ApoB (g/L)1.03 ± 0.23\*\*0.87 ± 0.189.4180.000ApoAI / ApoB1.24 ± 0.50\*\*1.54 ± 0.53−7.2260.000Lp(a) (mg/L)250.02 ± 183.39227.80 ± 168.161.5830.114ApoCIII (mg/dL)16.36 ± 6.20\*\*10.95 ± 4.4512.5760.000Data are expressed as mean ± SD. FBS: Fasting blood sugar; TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; ApoAI: Lipoprotein AI; ApoB: Lipoprotein B; Lp(a): Lipoprotein a; ApoCIII: Apolipoprotein CIII; ^\*\*^ *P* \< 0.01, atherosclerotic patients versus healthy controls analyzed using *t-*tests Table 7Comparison of lipid profiles of atherosclerotic patients (AS) and healthy controls (control) in the Li and Han ethnic groupsParameterLi ethnicityHan ethnicityAS (*n* = 155)Control (*n* = 158)*P-*valueAS (*n* = 161)Control (*n* = 154)*P-*valueTC (mmol/L)5.12 ± 1.294.99 ± 0.760.2735.04 ± 0.89\*\*4.54 ± 0.770.000TG (mmol/L)1.34 ± 0.78\*1.18 ± 0.590.0391.54 ± 1.18\*\*1.13 ± 0.730.000HDL-C (mmol/L)1.20 ± 0.40\*\*1.33 ± 0.290.0021.04 ± 0.34\*\*1.21 ± 0.330.000LDL-C (mmol/L)3.10 ± 1.022.90 ± 0.730.0583.22 ± 0.78\*\*2.76 ± 0.730.000ApoAI (g/L)1.28 ± 0.41\*\*1.39 ± 0.340.0091.12 ± 0.291.17 ± 0.310.150ApoB (g/L)0.96 ± 0.24\*\*0.84 ± 0.160.0001.11 ± 0.24\*\*0.89 ± 0.190.000ApoAI/ApoB1.40 ± 0.55\*\*1.70 ± 0.520.0001.09 ± 0.21\*\*0.90 ± 0.190.000Lp (a) (mg/L)238.4 ± 161.4225.3 ± 152.80.460247.9 ± 176.6232.8 ± 165.50.434ApoCIII (mg/dL)15.83 ± 6.12^\*\*^11.49 ± 4.510.00016.87 ± 6.25\*\*10.39 ± 4.340.000Data are expressed as mean ± SD. TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; ApoAI: Lipoprotein AI; ApoB: Lipoprotein B; Lp(a): Lipoprotein a; ApoCIII: Apolipoprotein CIII; ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01, atherosclerotic patients versus healthy controls in the Li and Han ethnic groups analyzed using *t-*tests

Lipid profiles of S1 and S2 allele carriers among the atherosclerotic patients and healthy controls in the li and Han ethnic groups {#Sec15}
-----------------------------------------------------------------------------------------------------------------------------------

In the Li ethnic group, S2 allele carriers exhibited increased plasma apoCIII levels compared to those of S1 allele carriers among the atherosclerotic patients (*P* \< 0.01), while the S2 allele carriers showed increased TG and apoCIII levels among the healthy controls (*P* \< 0.01; *P* \< 0.05) (Table [8](#Tab8){ref-type="table"}). In the Han ethnic group, S2 allele carriers exhibited increased TG levels compared to S1 allele carriers among the atherosclerotic patients, while S2 allele carriers showed increased plasma apoCIII levels among the healthy controls (*P* \< 0.01) (Table [9](#Tab9){ref-type="table"}).Table 8Lipid profiles between S1 allele carriers and S2 allele carriers in the Li ethnic groupParameterAS (n = 155)Control (n = 158)S1S1 (*n* = 82)S1S2 + S2S2 (*n* = 73)*P*-valueS1S1 (*n* = 122)S1S2 + S2S2 (*n* = 36)*P*-valueTC (mmol/L)5.12 ± 1.325.13 ± 1.290.9564.95 ± 0.785.12 ± 0.720.259TG (mmol/L)1.26 ± 0.631.43 ± 0.920.1661.07 ± 0.441.53 ± 0.84^\*\*^0.003HDL-C (mmol/L)1.26 ± 0.421.14 ± 0.360.0641.33 ± 0.291.32 ± 0.290.982LDL-C (mmol/L)3.03 ± 0.993.17 ± 1.050.4052.90 ± 0.722.91 ± 0.770.917ApoAI (g/L)1.29 ± 0.431.26 ± 0.390.6441.41 ± 0.361.33 ± 0.260.243ApoB (g/L)0.94 ± 0.220.98 ± 0.260.2600.85 ± 0.160.83 ± 0.150.610ApoAI/ApoB1.44 ± 0.581.36 ± 0.520.3621.72 ± 0.531.66 ± 0.490.569Lp(a) (mg/L)254.0 ± 168.1218.8 ± 156.30.181231.5 ± 164.1208.0 ± 101.30.298ApoCIII (mg/dL)14.07 ± 5.2117.81 ± 6.48^\*\*^0.00010.90 ± 3.9613.53 ± 5.60^\*^0.012Data are expressed as mean ± SD. TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; ApoAI: Lipoprotein AI; ApoB: Lipoprotein B; Lp(a): Lipoprotein a; ApoCIII: Apolipoprotein CIII; ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01, S1 allele carriers versus S2 allele carriers in the Li ethnic group analyzed using the Kruskal--Wallis or Wilcoxon--Mann--Whitney tests Table 9Lipid profiles in S1 allele carriers and S2 allele carriers in the Han ethnic groupParameterAS (*n* = 151)Control (n = 154)S1S1 (*n* = 83)S1S2 + S2S2 (*n* = 78)*P*-valueS1S1 (*n* = 117)S1S2 + S2S2 (*n* = 37)*P*-valueTC (mmol/L)4.92 ± 0.795.18 ± 0.970.0654.52 ± 0.774.60 ± 0.780.622TG (mmol/L)1.27 ± 0.541.84 ± 1.56\*\*0.0031.06 ± 0.531.36 ± 1.130.122HDL-C (mmol/L)1.08 ± 0.370.99 ± 0.290.1171.23 ± 0.361.14 ± 0.250.089LDL-C (mmol/L)3.17 ± 0.733.28 ± 0.820.3892.76 ± 0.742.77 ± 0.700.895ApoAI (g/L)1.11 ± 0.291.13 ± 0.290.6821.15 ± 0.311.24 ± 0.290.097ApoB (g/L)1.07 ± 0.211.10 ± 0.210.2660.97 ± 0.200.86 ± 0.170.291ApoAI/Apo B1.10 ± 0.421.10 ± 0.340.5221.33 ± 0.521.48 ± 0.430.111Lp(a) (mg/L)244.6 ± 159.4251.4 ± 194.20.806222.3 ± 152.8265.8 ± 199.30.164ApoCIII (mg/dL)15.97 ± 5.8917.83 ± 6.510.0599.78 ± 3.8712.32 ± 5.15\*\*0.008Data are expressed as mean ± SD. TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; ApoAI: Lipoprotein AI; ApoB: Lipoprotein B; Lp(a): Lipoprotein a; ApoCIII: Apolipoprotein CIII; ^\*\*^ *P* \< 0.01, S1 allele carriers versus S2 allele carriers in the Han ethnic group analyzed using the Kruskal--Wallis or Wilcoxon--Mann--Whitney tests

Discussion {#Sec16}
==========

Our study confirmed the existence of the *Sst*I polymorphism in the *apoC3* gene in the Li ethnic group, with increased frequencies of the S1S2 and S2S2 genotypes and the S2 allele found in atherosclerotic patients. Furthermore, the S2 allele was associated with an increased risk of atherosclerosis.

The S2 allele, unfavorable lipid profiles (increased FBS, TG, TC, LDL-C, apoB, and apoCIII; decreased HDL-C, apoAI and lower apoAI:apoB ratio) and environmental risk factors, such as elevated waist circumference and increased systolic and diastolic pressure were found to promote the development of atherosclerosis. We identified variations in these results when we investigated lipid profiles and the roles they played in atherosclerosis susceptibility in the Li and Han ethnic groups. According to our results, the S2 allele was consistently associated with plasma apoCIII in the Li population, while the association with plasma TG existed only in the healthy controls in this ethnic group. Based on the association of apoCIII with TG reported in a previous study \[[@CR10], [@CR15]--[@CR17]\], we speculate that apoCIII might represent a link between the S2 allele and plasma TG levels, although this was not the only parameter which affected plasma TG, especially in the presence of atherosclerosis. In the Han population, the S2 allele was associated with increased plasma TG levels in the atherosclerotic group and with increased plasma apoCIII levels in the healthy controls. The variation in the association of the S2 allele with plasma TG or apoCIII levels indicated the importance of our study. The S2 allele and elevation of either plasma apoCIII or TG were found to be associated with the development of atherosclerosis in both the Li and Han ethnic groups. The *Sst*I polymorphism in the *apoC3* gene was also shown to influence the risk of atherosclerosis. In contrast, a recent study showed that non-mutated *apoC3* gene carriers exhibited a favorable lipid profile, and revealed strong genetic evidence implicating the S2 allele in the development of atherosclerosis \[[@CR18], [@CR19]\].

Our study revealed the association of the S2 allele with plasma apoCIII levels, which combined with unfavorable lipid profiles and environmental risk factors, contributed to the development of atherosclerosis in the Li ethnic group. Thus, it can be hypothesized that ApoCIII functions as a link between the S2 allele and plasma TG levels, although the exact mechanism of the interactions among the S2 allele and the levels of plasma apoCIII and TG remain to be clarified.

Conclusions {#Sec17}
===========

The association of the S2 allele of the *Sst*I polymorphism in the *apoC3* gene with plasma apoCIII levels interacts with unfavorable lipid profiles to contribute to the development of atherosclerosis in the Li population in China.
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